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Abstract
Objective—The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
examined the comparative effectiveness of antipsychotic treatments for individuals with chronic
schizophrenia. Patients who had discontinued antipsychotic treatment in phases 1 and 2 were eligible
for phase 3, in which they selected one of nine antipsychotic regimens with the help of their study
doctor. We describe the characteristics of the patients who selected each treatment option and their
outcomes.
Method—Two hundred and seventy patients entered phase 3. The open-label treatment options were
monotherapy with oral aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone,
ziprasidone, long-acting injectable fluphenazine decanoate, or a combination of any two of these
treatments.
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Results—Few patients selected fluphenazine decanoate (n=9) or perphenazine (n=4). Similar
numbers selected each of the other options (range 33–41). Of the seven common choices, those who
selected clozapine and combination antipsychotic treatment were the most symptomatic, and those
who selected aripiprazole and ziprasidone had the highest body mass index. Symptoms improved
for all groups, although the improvements were modest for the groups starting with relatively mild
levels of symptoms. Side effect profiles of the medications varied considerably but medication
discontinuations due to intolerability were rare (7% overall).
Conclusions—Patients and their doctors made treatment selections based on clinical factors,
including severity of symptoms, response to prior treatments, and physical health status.
Fluphenazine decanoate was rarely used among those with evidence of treatment non-adherence and
clozapine was underutilized for those with poor previous response. Combination antipsychotic
treatment warrants further study.
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Schizophrenia; clinical trial; antipsychotic; effectiveness
1.0 Introduction
Several recent studies, including the Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) schizophrenia project, the Cost Utility of the Latest Antipsychotic Drugs in
Schizophrenia Study (CUtLASS), and the European First-Episode Schizophrenia Trial
(EuFEST) sought to provide objective evidence regarding the comparative effectiveness of
antipsychotic drugs in real-world settings (Jones et al. 2006; Kahn et al. 2008; Lewis et al.
2006; Lieberman et al. 2005). The National Institute of Mental Health (NIMH) initiated the
CATIE schizophrenia project to determine the comparative effectiveness of antipsychotic
drugs for individuals with chronic schizophrenia in typical clinical settings and situations in
the United States (Stroup et al. 2003). Intended to mirror typical clinical practice, in which
individuals with schizophrenia may require multiple medication trials before finding one that
is adequately efficacious and tolerable, the CATIE study design allowed for patients who
discontinued one study antipsychotic drug to enter subsequent phases of the study to receive
additional antipsychotics.
The main results of all randomized phases of the CATIE study, including the initial random
assignment (to olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone—phases 1
and 1A), phase 1B (involving patients who discontinued perphenazine in phase 1), and the
efficacy and tolerability arms of the second phase (phases 2E and 2T) have been reported.
(Lieberman et al. 2005; McEvoy et al. 2006; Stroup et al. 2007; Stroup et al. 2006) In this
article we present results of phase 3, in which participants who discontinued either arm of phase
2 could select, with the assistance of their study doctor, from nine antipsychotic treatment
regimens. The purpose of phase 3 was to allow participants to stay in the study for the entire
scheduled 18 months and to gather systematic data on the efficacy, safety, and tolerability of
these treatment regimens when selected and used openly.
2.0 Experimental Methods
2.1 Study Setting and Design
The goal of the CATIE schizophrenia study was to examine the comparative effectiveness of
antipsychotic drugs. Its rationale, design, and methods were previously described in detail.
(Davis et al. 2003; Keefe et al. 2003; Stroup et al. 2003; Swartz et al. 2003) The study was
conducted between January 2001 and December 2004 at 57 U.S. clinical sites. Figure 1 details
the enrollment, treatments, and follow-up of patients in the study. Patients were initially
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randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone
under double-blind conditions and followed for up to 18 months or until treatment was
discontinued for any reason. In phase 2, patients discontinuing from phase 1, 1A or 1B and
their study doctors could choose between two randomization pathways.(Stroup et al. 2003)
Patients who discontinued treatment in phase 2 before study completion were eligible for phase
3. In phase 3, participants selected openly from the following nine possible treatment regimens:
antipsychotic monotherapy with oral aripiprazole, clozapine, olanzapine, perphenazine,
quetiapine, risperidone, or ziprasidone; long-acting injectable fluphenazine decanoate; or a
combination of any two of these treatments.(Stroup et al. 2003) If the selected treatment was
not discontinued because of inadequate efficacy, intolerability, or any other reason, patients
could continue taking this regimen until the completion of 18 months of study treatment. The
ziprasidone and aripiprazole options were added after approximately 20% and 65% of patients
had enrolled in phase 3, respectively, after the FDA approved these treatments.
2.2 Participants
The initial inclusion criteria required an age of 18 to 65 years, a diagnosis of schizophrenia
(determined by the Structured Clinical Interview for DSM-IV), and appropriateness for oral
antipsychotic medication.(Stroup et al. 2003) The exclusion criteria were a diagnosis of
schizoaffective disorder; diagnosis of mental retardation or other cognitive disorder; past
serious adverse reaction to any of the proposed treatments; first episode of schizophrenia;
history of treatment resistance, defined by persistence of severe symptoms despite an adequate
trial of one of the proposed treatments or prior treatment with clozapine for treatment resistance;
current pregnancy or breast-feeding; or serious and unstable medical condition. If patients
discontinued perphenazine in phase 1, then they entered phase 1B and then either phase 2E or
2T before enrolling in phase 3.
The study was approved by an institutional review board at each site, and written informed
consent was obtained from each patient or the patient’s legal guardian.
2.3 Interventions
Patients and study physicians selected medication regimens in phase 3 based on the clinical
situation of each individual. To help inform the choice, patients entering phase 3 and their
clinicians were informed about which medications had been assigned to that patient in previous
phases of the study. In order to protect the blind in earlier phases of the study, this unblinding
at the outset of phase 3 occurred after all assessments for the previous phase had been completed
and entered into the data system. In addition, the previous drug names were provided
alphabetically rather than chronologically in order to protect the study blind. Medications taken
by a patient in previous phases of the trial were allowed both as a lone antipsychotic and as
one drug in combination treatment during phase 3.
All of the study medicines in phase 3 were flexibly dosed on the basis of the study doctor’s
judgment. Overlap in the administration of the antipsychotic that the patient received in the
prior phase was permitted for the first 4 weeks to allow for gradual transition to the new
medication regimen. Concomitant medications were permitted throughout the trial, except
additional antipsychotics. The patients had monthly visits with study doctors, until their total
CATIE study participation across all phases reached 18 months, or they discontinued the phase
3 treatment for any reason. Because patients entered phase 3 after different durations of study
participation, there was a wide range of possible treatment durations in Phase 3.
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2.4 Objectives and Outcomes
Our objective was to gather systematic data on the overall effectiveness of common
antipsychotic treatments. We had no a priori hypotheses to test, but instead examined the
overall effectiveness of the drugs, including measures of efficacy and safety. As in other phases
of the CATIE schizophrenia trial, the primary outcome measure of interest was treatment
discontinuation for any cause; this discrete outcome measure reflects the enduring acceptability
of a medication and integrates patient and clinician judgments of efficacy, safety, and
tolerability into a global measure of effectiveness. We also examined the reason for treatment
discontinuation as judged by the study doctor. Additional secondary efficacy outcomes
included scores on the Positive and Negative Syndrome Scale (PANSS) and Clinical Global
Impression scale (CGI), which were collected at study baseline and after 1, 3, 6, 9, 12, 15, and
18 months of study participation, as well as any visit in which there was a transition from one
phase to another (e.g., beginning and end of Phase 3). Secondary safety and tolerability
outcomes included incidence of serious adverse events, incidence of treatment-emergent
adverse events, and changes in weight, measures of neurologic side effects, and laboratory
analytes.
2.5 Statistical Methods
Since there were no a priori hypotheses, and treatment regimens were openly selected, all
statistical testing is intended for descriptive purposes only. No adjustment was made for
multiple comparisons due to the number of treatment groups nor the number of parameters
evaluated.
The nine treatment regimens were compared at baseline for continuous parameters with an 8
degree of freedom analysis of variance (ANOVA) test, with the exception of laboratory
parameters which were compared with a Kruskal-Wallis rank test. Groups were compared for
baseline categorical outcomes with a chi-squared test, or Fisher’s exact test.
Groups were compared for Phase 3 discontinuation rates using a chi-squared or Fisher’s exact
test. Time to discontinuation was estimated via Kaplan-Meier survival curves, and evaluated
with a logrank test. Duration in phase 3 was evaluated with an ANOVA. Compliance and
duration as a percent of available study months were evaluated with a Kruskal-Wallis rank test.
Treatment regimens were compared for change from phase 3 baseline for PANSS and CGI-
severity scores at 3 months and 6 months of Phase 3 participation using an analysis of
covariance (ANCOVA) with adjustment for the baseline value. A within-sample t-test
evaluated whether the PANSS change was different from zero. Since assessments were
collected at various points relative to baseline, for each patient, data is from the latest post-
baseline measurement collected within the windows of 0–3 and 4–6 months.
Groups were compared for categorical safety and tolerability outcomes with Poisson regression
accounting for each patient’s duration of Phase 3 participation, or Fisher’s exact test in the case
of small counts. Change in laboratory parameters from baseline to the average of the two largest
reported values in Phase 3 are presented with baseline- and exposure-adjusted ANCOVA least
squares means, but due to skewed distributions, p-values comparing groups are from a ranked
ANCOVA adjusting for baseline and duration of Phase 3 study participation. Weight and QTc
changes were evaluated with ANCOVA adjusting for baseline value (for weight) and duration
of participation in phase 3.
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3.1 Patient Characteristics and Disposition
Figure 1 shows the flow of patients in the study. Of the 410 who were eligible for phase 3, 270
(66%) enrolled. The baseline demographic and diagnostic characteristics of subjects who
entered phase 3 were generally representative of the original study participants. The mean age
of subjects was 40.5 years (SD 11.0); 70% were men, 67% were white, 30% black, and 3%
were from other races. (See supplemental table.) There were no substantial demographic or
diagnostic differences between the groups of patients who selected the various treatments.
Table 1 reveals that there were substantial differences in the clinical characteristics of patients
who selected, with the guidance of study physicians, the nine treatment strategies offered.
Similar numbers of subjects selected 7 of the 9 antipsychotic medication strategies (33 to 41
participants for each). Single first-generation antipsychotics were used much less often--only
nine individuals selected fluphenazine decanoate and four selected perphenazine. Because of
these small numbers we will limit further discussion of treatment with these two first-
generation antipsychotic drugs. Among the 40 patients who selected combination treatment,
no specific pair of antipsychotics was selected by more than five patients; because of these
small numbers all patients selecting combination treatment have been pooled together. The
frequency of the various combinations can be seen in Table 2. Individual antipsychotics were
selected to be one of the pair combinations by the following number of patients: aripiprazole
8, clozapine 11, fluphenazine decanoate 6, olanzapine 11, perphenazine 10, quetiapine 14,
risperidone 15, and ziprasidone 8.
Patients who selected clozapine were earlier in the course of illness than those who selected
all the other drug treatments (mean 8.3 years since first antipsychotic treatment for clozapine
compared to 11.8–16.1 years for all others). Patients who selected clozapine and combination
antipsychotic treatment were more symptomatic, as indicated by total PANSS scores (mean
85.3–88.6), and patients selecting ziprasidone were less symptomatic (71.4) than patients who
selected the other oral second-generation antipsychotics (75.2–77.6). The small number of
patients selecting a first generation antipsychotic had high PANSS scores, which had worsened
since the beginning of the study.
Patients with the highest BMI selected aripiprazole and ziprasidone (mean BMI 34.3 for both)
compared to all the other treatment options (mean BMI 26.7–31.7). In general, these same
patients had gained more weight since study baseline than patients in the other groups, and
also had the highest blood glucose and glycosolated hemoglobin levels. There were no
remarkable differences in total cholesterol or triglyceride levels between the treatment groups
at the beginning of phase 3.
Patients who selected clozapine, ziprasidone, and aripiprazole had been in the study longer
(mean 8.6, 9.4, and 9.5 months, respectively) than those who selected all the other drugs (4.0
to 7.6 months). Because ziprasidone became available after 20% of patients had enrolled in
phase 1/1A, and aripiprazole after approximately 65%% of patients had enrolled, the time to
selecting these newest two drugs likely reflects the logistics of the study.
Most patients who selected clozapine (78%) or combination antipsychotic treatment (65%) in
phase 3 had discontinued the previous treatment due to inadequate efficacy on the previous
drug. Only 33% who selected quetiapine had stopped the previous drug due to inadequate
efficacy, while for all the other study treatment options the range was 42–50%. Only 3% of
patients who selected clozapine had discontinued the previous treatment due to unacceptable
side effects. On the other end of the spectrum, unacceptable side effects were cited as the cause
for discontinuation in phase 2 by a substantial portion of patients who selected quetiapine
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(46%), aripiprazole (39%), and ziprasidone (35%). Weight or metabolic problems were the
reason the phase 2 antipsychotic was discontinued for 27% and 19% of patients who selected
aripiprazole and ziprasidone in phase 3, while none of these patients selected clozapine or
olanzapine.
The mean modal doses of each treatment are in Table 3. The proportion of phase 3 study visits
at which patients were judged, using pill counts and any other clinical information available
to study clinicians, to have taken prescribed medication always or almost always was lowest
for risperidone (61%) compared to all the other treatments (77–86%).
3.2 Treatment Discontinuation
In phase 3, 106 of the 270 patients (39%) discontinued treatment before completion of the
study. The mean treatment duration was 7.7 months, which corresponds to an average of 75%
of the maximum possible participation time. Discontinuation outcomes are presented in Table
3. There were no substantial differences between treatments in the proportion of patients who
discontinued the commonly selected medication regimens (range 33–46%) or in the proportion
of possible treatment time that patients stayed on treatment (range 67–80%). The rates of
discontinuation for lack of efficacy were lower for clozapine, risperidone, quetiapine, and
ziprasidone (0–5%) compared to aripiprazole, olanzapine, combination antipsychotic
treatment, and olanzapine (13–18%).
3.3 Efficacy Measures
The results of the PANSS and CGI analyses are presented in Table 4. There were no differences
in the PANSS total or subscale score changes among the treatment groups at 3 months or 6
months. Using a within-sample t-test for change on the PANSS total score from baseline with
p=0.05 as an indicator of substantial change, all of the commonly used treatments were
associated with substantial symptom improvement at 3 months and 6 months, with the
exception of aripiprazole at 3 months and both quetiapine and ziprasidone at 6 months.
3.4 Adverse Events and Safety Outcomes
Adverse events, side effects, and laboratory results are listed in Table 5. When we accounted
for multiple hospitalizations and for the differential time in treatment we found the rates ranged
from 0.21 hospitalizations per person-year of exposure for risperidone to 0.45 for aripiprazole
and ziprasidone, and 0.49 for combination antipsychotic treatment. The rates of spontaneous
adverse events rated as moderate or severe were lowest for olanzapine and risperidone (17%
for each) and highest for quetiapine (45%), clozapine (35%), and combination antipsychotic
treatment (30%).
Anticholinergic side effects were common with quetiapine (36%) and not reported at all for
risperidone, with all the other drugs intermediate (11–25%). Incontinence or nocturia were
most common with clozapine (19%) and olanzapine (12%) and 5% or lower for the other
treatments. Sialorrhea and orthostatic faintness were reported much more commonly with
clozapine (38% and 24% respectively) than with all other treatment groups (0–12%).
Among the commonly selected treatments, clinically significant weight gain of at least 7% was
most common for clozapine (32%), combination antipsychotic treatment (39%) and olanzapine
(23%); the rates were lowest for aripiprazole and ziprasidone (both 7%). Mean weight gain per
month of treatment was highest for clozapine (1.3 pounds) and olanzapine (1 pound). All the
other second-generation antipsychotics were associated with weight loss, with the most
monthly weight loss associated with aripiprazole (1.4 pounds) and ziprasidone (1.3 pounds).
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Exposure-adjusted blood glucose increased the most for patients taking aripiprazole and
increased for those taking clozapine and quetiapine but declined for patients taking all the other
treatment regimens. Only risperidone among the second-generation antipsychotics was
associated with substantial increases in prolactin levels.
Anxiolytics were added for a higher proportion of patients on combination antipsychotic
regimens (23%) as compared to quetiapine (15%), olanzapine (12%), and the other second-
generation antipsychotics (0–6%).
4.0 Discussion
The results presented here provide additional information on the use and effectiveness of
antipsychotic medications commonly used by patients with chronic schizophrenia. The
differences in the clinical status of patients at the time of entry into Phase 3 can be interpreted
to reflect the views of study clinicians and participating patients regarding the selection of
antipsychotics during the years the study was conducted (2001–2004). The study provides new
information from CATIE about aripiprazole and combination antipsychotic treatment.
Very few patients and clinicians selected antipsychotic monotherapy with a first-generation
antipsychotic, reflecting the dominance of second-generation drugs among antipsychotic
prescriptions in the United States. Long-acting fluphenazine decanoate was used by only 3%
of patients in phase 3 although only 77% of patients in phase 2 were judged by clinicians to
be always or almost always compliant with their antipsychotic medication regimen.
Clozapine and combination antipsychotic treatment regimens were frequently selected by
patients with relatively severe psychopathology and by those who stopped the previous
medication due to inadequate therapeutic effect. Although clozapine is the only treatment
consistently shown to be effective when others are not (Chakos et al. 2001), it was used by
only 11% (37 of 270) of patients in phase 3 although 51% (138 of 270) had discontinued the
previous medication due to inadequate therapeutic effect. When used, clozapine was selected
by patients who reached phase 3 more quickly than patients who selected the other medicines,
suggesting that it was used for individuals who were repeatedly not getting adequate symptom
reduction and quickly failing trials on other medications.
This is the first report from CATIE regarding aripiprazole, which was not available when the
study began and was not included in other study phases. Aripiprazole and ziprasidone were
selected by patients with the highest body mass indexes and most weight gain during the trial,
and for those with the highest blood glucose and glycosolated hemoglobin levels. Aripiprazole
was similar to all the other treatments in the proportion of patients who discontinued treatment
for any reason. Aripiprazole was almost identical to ziprasidone both in the small proportion
of patients with clinically significant weight gain and in average weight loss per month.
However, aripiprazole was associated with greater increases in blood glucose than all of the
other treatment regimens. This is not what would be expected from a recent systematic review
that found no clear trends among antipsychotic drugs and blood sugar changes (Bushe and
Leonard 2007). Given the lack of concordance of this finding with larger studies that used
random assignment to treatments, the most likely explanation for the finding is chance. Another
possible explanation for this finding, given that those who chose aripiprazole treatment had
among the highest blood glucose levels at baseline and high rates of previous medication
discontinuations due to intolerability, is that pre-existing problems with glucose metabolism
at baseline deteriorated further in phase 3. However, those treated with ziprasidone in phase 3
had the highest mean levels of blood glucose at baseline and blood glucose for this group
declined in phase 3. Because treatment with aripiprazole is a common medication choice for
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individuals with metabolic problems, this finding of increased blood glucose may deserve
additional investigation.
Weight change in the study prior to entry in phase 3 was greatest for those who selected
aripiprazole and ziprasidone, and the mean BMI was higher for these patients than for those
selecting other drugs. The weight loss associated with these drugs may therefore be due to the
removal of previous weight-gain inducing drugs or simply regression to the mean. However,
the findings may still be relevant to practitioners because these medicines are commonly chosen
preferentially for patients in clinical situations who are overweight just as they were in phase
3. It is also notable that clozapine, combination treatment, and olanzapine were associated with
weight gain even though patients selecting these options had also gained weight during earlier
phases of the study.
The mean modal doses of olanzapine and risperidone used in this open label phase of CATIE
are quite similar to those used in previous phases that involved patients not selected because
of persistent symptoms (i.e., phases 1/1A, 1B and 2T) (Lieberman et al. 2005; Stroup et al.
2007; Stroup et al. 2006). On the other hand, ziprasidone was used at a somewhat higher dose
in phase 3 (132.1 mg/day) compared to both blinded phases in which it was used (112.8 mg/
day in phase 1/1A and 115.9 mg/day in phase 2T) while quetiapine was used at a lower dose
in phase 3 (500 mg/day) compared to the doses in blinded phases (543.4–586.1 mg/day). It is
possible that the doses of quetiapine and ziprasidone used in this open-label phase more closely
resemble usual practice than the doses used in blinded phases of the study.
Patients with chronic schizophrenia who entered phase 3 of the CATIE schizophrenia trial had
discontinued two consecutive second-generation antipsychotics before choosing a phase 3
treatment regimen. Levels of psychopathology, the reason for previous treatment
discontinuation, and indicators of metabolic functioning seemed to guide treatment selection.
Clinicians and patients did not, however, closely follow evidence-based clinical
recommendations that suggest using clozapine for individuals with poor treatment response
and the use of long-acting injectable medications when treatment adherence is a problem
(Lehman et al. 2004). Clozapine was underutilized for people with poor therapeutic response,
and fluphenazine decanoate was rarely used in spite of the high prevalence of medication non-
adherence in individuals with schizophrenia. We again found variation in the adverse effects
associated with antipsychotic medications that may help guide patients and clinicians in making
treatment choices. Combination antipsychotic treatment was a common strategy that warrants
further systematic study.
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